All News
#EULAR2021 #EULAR21 #eular #spondyloarthritis
I have always thought we named nr-axSPA wrongly - Tends to trivialise its gravity and importance
Shouldn’t it be our goal to diagnose all SpA at the nr-axSPA stage
@deodhara @NigilHaroon https://t.co/zwKI1o9WcO
EnvisionRheumat ERheumat ( View Tweet)
Patient profiles have changed in clinical trials of PsA #EULAR2021 https://t.co/6l2RfOPkSq
Dr Irwin Lim _connectedcare ( View Tweet)
#EULAR2021: AxSpA patients with greater patient-reported pain and spinal pain relative to axPsA patients among real-world patients in CorEVitas' Psa/Spa observational Registry per Dr. Mease's oral abstract presentation. @RheumNow https://t.co/YEdhd7x6cb
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#EULAR2021 - Key points from Dr. Mease's oral abstract:
⭐️AxSpA pts were younger & more likely to be male & have a hx of uveitis & IBD
⭐️AxSpA pts had less exposure to prior therapies relative to axPsA pts
⭐️AxSpA assoc w/ > spinal pain regardless of b/tsDMARD status
@Rheumnow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#EULAR2021: AxSpA patients more likely to experience IBD and uveitis whereas axPsA more likely to experience dactylitis and enthesitis per Dr. Philip Mease's study among real-world patients in CorEVitas' Psa/Spa Registry.
@RheumNow https://t.co/g2m5fylFJj
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#EULAR2021: SpA pts w/ predominant axial phenotype tended to be HLAB27+ & have uveitis whereas those w/ predom peripheral phenotype tended to have arthritis, dactylitis, or psoriasis & fit a clinical dx of axSpA & psSpa (incl psA) respectively per this observat study. @RheumNow https://t.co/E5UTbc6Sqb
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#EULAR2021 bDMARD and TNF-i naive patients w/ r-axSpA without evidence of objective inflammation (normal CRP & MRI ) showed ASA40 response w/ ixekizumab @RheumNow https://t.co/5KT8A81auq
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#OP0089 Do you know the pain catastrophizing score #PCS ? Cross-sectional study of 1199 #RA, #PsA & #ax-SpA patients: Low PCS were more often in remission as high PCS in RA & ax-SpA. PCS was associated with remission rates in RA and ax-SpA, but not in PsA #EULAR2021 @RheumNow https://t.co/MYiLmPPbDN
Paul Studenic Stiddyo ( View Tweet)
#EULAR2021: "I am an advocate for smart T2T, not a mathematical T2T approach." - Dr. Filip van den Bosch @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#EULAR2021: In India, some of the JAKi are costing less than $30/mo per a EULAR participant! Dr. Filip van den Bosch does not recommend using tofacitinib as a diagnostic tool for SpA over NSAIDs even if it is so cheap. @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#EULAR2021: Reduced likelihood of reaching disease remission in patients with RA or PsA who have concomitant depression and anxiety per prospective NOR-DMARD study. Social state and mental health factors play an important role in noresponse in T2T approach. @RheumNow https://t.co/Vl0Xkz2SNF
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#EULAR2021: Dr. Filip van den Bosch recommends the "DEER" treatment approach for SpA: Dedicated Empathic and Educated Rheumatologist! @RheumNow https://t.co/W0jbGXk7q8
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Prof. Alten outlined the value of patient-reported outcomes for clinical practice!
How do you collect patient-reported outcomes - PRO - in your rheumatology clinic?
#EULAR2021 @RheumNow
Paul Studenic Stiddyo ( View Tweet)
Skin fibroblasts in #CRPS: Immunohistological staining of NT3 showed higher expression in the affected vs. not affected side. Increasing NT3 expression <> pain increase.
-->dysregulated communication of #fibroblasts with the sensory nerve fibers. #OP0085 #EULAR2021 @RheumNow
Paul Studenic Stiddyo ( View Tweet)
#OP0049 corevitas observational registry: ax-SpA patients showed younger age, more males, greater spinal pain, more exposure to cs- or bDMARD but similar fatigue and work impairment compared to ax-PsA #EULAR2021 @RheumNow
Paul Studenic Stiddyo ( View Tweet)
#EULAR2021: If we review ASAS40 response from infliximab to tofacitinib, then there has not been much evolution in efficacy of therapy for SpA in the past 20 yrs. This suggests we haven't been looking at the right endpoint in measuring efficacy! MDA instead!
@RheumNow https://t.co/E61yb97CRN
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#Eular2021: There is no diagnostic criteria for nr-AxSpA, but there is a diagnostic approach that entails collecting clinical information and imaging to visualize inflammation or post-inflammatory changes of the axial skeleton. @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#Eular2021: Do you start a bDMARD for nr-AxSpa without objective evidence of inflammation (elevated CRP, negative structural damage on MRI)? @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#Eular2021 "Just because they do not have nonradiographic-AxSpa, it does not mean that the disease burden is less (compared to radiographic-AxSpa)!" Dr. Atul Deodhar @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Crosssectional multicentre study clusters phenotypes of #spondyloarthritis differentiating two types: axial and peripheral, Fitted well to either diagnoses of ax-SpA or #PsA. Still overlap of features like arthritis, dactylitis and enthesitis exists. #OP0047 #EULAR2021 @RheumNow https://t.co/sru9bT4mla
Paul Studenic Stiddyo ( View Tweet)